# Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

Source: https://onco.cc/trials/nct06496048/  
OnCo record `nct06496048` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Lurbinectedin, FOLFIRI, Topotecan in small-cell lung cancer, run by Luye Pharma Group Ltd., now recruiting.

## Summary

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC is a phase 3 interventional study registered as NCT06496048 by Luye Pharma Group Ltd., with 180 participants planned, started 2024-09-14 and due to reach its primary completion in 2027-12-31. Interventions recorded: Lurbinectedin, Irinotecan, Lurbinectedin, Topotecan. Conditions listed: Relapsed Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06496048
- Phase: 3
- Setting: A Phase III, Multicenter, Randomized, Open-label Study of Lurbinectedin As Monotherapy or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed Small-cell Lung Cancer (SCLC)
- Sponsor: Luye Pharma Group Ltd.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT06496048: https://clinicaltrials.gov/study/NCT06496048

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Lurbinectedin](https://onco.cc/drugs/lurbinectedin/), [Topotecan](https://onco.cc/drugs/topotecan/)
- companies: [Luye Pharma Group](https://onco.cc/companies/luye-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06496048.json